SCYNEXIS (SCYX) Earns Daily Media Sentiment Rating of -0.06

News coverage about SCYNEXIS (NASDAQ:SCYX) has been trending somewhat negative on Wednesday, AlphaOne Sentiment reports. The research group, a subsidiary of Accern, scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SCYNEXIS earned a media sentiment score of -0.06 on AlphaOne’s scale. AlphaOne also assigned media coverage about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s analysis:

Several equities research analysts recently weighed in on SCYX shares. HC Wainwright set a $14.00 price target on SCYNEXIS and gave the stock a “buy” rating in a research note on Saturday, April 15th. Zacks Investment Research raised SCYNEXIS from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Friday, March 17th. Guggenheim reaffirmed a “buy” rating and issued a $15.00 price target on shares of SCYNEXIS in a research note on Tuesday, March 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of SCYNEXIS in a research note on Friday, March 3rd. Finally, Aegis reaffirmed a “buy” rating on shares of SCYNEXIS in a research note on Tuesday, May 30th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $10.56.

SCYNEXIS (SCYX) traded down 0.60% during midday trading on Wednesday, hitting $1.66. The stock had a trading volume of 99,467 shares. The stock’s market cap is $42.82 million. The company’s 50 day moving average price is $2.08 and its 200-day moving average price is $2.90. SCYNEXIS has a 52-week low of $1.55 and a 52-week high of $5.51.

In other SCYNEXIS news, CEO Marco Taglietti bought 25,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were purchased at an average cost of $1.69 per share, for a total transaction of $42,250.00. Following the purchase, the chief executive officer now directly owns 277,000 shares in the company, valued at $468,130. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gonzalez David Angulo bought 15,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were acquired at an average price of $1.70 per share, for a total transaction of $25,500.00. Following the completion of the purchase, the insider now owns 62,000 shares in the company, valued at $105,400. The disclosure for this purchase can be found here. Insiders own 3.91% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Mideast Time and is the property of of Mideast Time. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.mideasttime.com/scynexis-scyx-earns-daily-media-sentiment-rating-of-0-06/1760642.html.

About SCYNEXIS

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:SCYX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for SCYNEXIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.